Gerresheimer's 40% Rally Masks an Accounting Quagmire and a June Audit Cliff

Gerresheimer's 40% surge hides an accounting scandal, creditor deadlines, and a planned Centor sale. Stock down 60% over 12 months as investors await audit results.

Gerresheimer shares have surged more than 40% over the past month, but the rebound tells only half the story. Beneath the chart lies a company still wrestling with an accounting scandal, creditor deadlines, and a planned divestiture that will test investor patience anew.

The stock touched a six-month high on Wednesday before profit-taking kicked in. By Friday it had slipped to €24.84, down 1.43% on the day. The weekly picture is less flattering: the primary article shows a 5% drop to €23.86 on Friday alone, reflecting the persistent nervousness around the packaging group’s financial health. Over a 12-month horizon, losses stand at 60.10%.

Creditors grant breathing room — for now

The heart of the crisis is a systematic violation of IFRS rules through bill-and-hold transactions, confirmed by an independent investigation. Gerresheimer booked revenue for goods not yet shipped. Germany’s financial regulator BaFin and the audit watchdog APAS are both reviewing the books.

On the financing side, the management has bought time. Banks and Schuldschein lenders extended the deadline for the audited annual accounts into the autumn and temporarily waived key leverage covenants. The company still aims to present the certified figures in June. Failure to obtain a clean audit opinion on the 2025 statements would jeopardise existing credit lines—a cliff the market is watching closely.

Centor sale gathers momentum

As part of the restructuring, Gerresheimer has put its profitable US subsidiary Centor on the block. Morgan Stanley is running the process, and management reports a double-digit number of interested parties. Centor’s book value stood at €292 million at the end of 2024. The cash from the sale is intended to shore up liquidity.

The board is also clearing the books of past overstatements. Write-downs for 2025 could reach as high as €240 million, primarily linked to the Sensile Medical project and the soon-to-close Chicago Heights plant. Despite these charges, the company reaffirmed its operational forecast: revenue of around €2.3 billion by 2026.

KPMG under the microscope

The accounting probe has widened to include the former auditor. APAS has initiated a professional conduct proceeding against KPMG, which issued an unqualified opinion on the 2024 financial statements. Those statements contained €35 million in erroneous revenue bookings. The case has cast doubt on the reliability of past audits and raised the stakes for the upcoming 2025 certification.

Goldman trims its stake while the AGM waits

Institutional sentiment remains guarded. Goldman Sachs reduced its overall position from 20.13% to 19.80% of voting rights, as reported on 7 May. The move is small in isolation, but in a company under such scrutiny, any shift from a major investor tends to amplify market unease.

Adding to the uncertainty, Gerresheimer postponed its ordinary annual general meeting—originally scheduled for early June—indefinitely. The delay stems from unresolved audit processes and a special review by a second auditing firm. Interims-CEO Uwe Röhrhoff is working to keep creditors onside, and reports suggest they have signalled continued support for now.

Technical picture: recovery without foundation

The stock currently trades 18.10% above its 50-day moving average, but remains below the 200-day line. The relative strength index of 28.1 signals elevated selling pressure in the near term. Market participants are treating the recent rally as a technical correction in a fundamentally impaired name, not the start of a sustained recovery.

Operationally, Gerresheimer continues to lean on its Medical Devices and biopharma solutions to offset inventory adjustments in the glass business. But until the audited accounts are published—and the impact of the Bormioli acquisition properly absorbed—the share price will oscillate between hope and hard numbers. The next key date is June, when the audit verdict and the credit line renewal will determine whether the rally has any real legs.